Gelteq Limited Ordinary Shares (GELS) Financial Ratios
5 years of historical data (2020–2024) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: N/A
ROE
↑
-21.0%
↓+54% vs avg
5yr avg: -45.5%
30Y Low-168%·High-5%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
GELS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $5M | — | — | — | — | — |
| Enterprise Value | $8M | — | — | — | — | — |
| P/E Ratio → | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
GELS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
GELS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have compressed from -2164.4% to -3885.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -21.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | 38.7% | 35.7% | — | — |
| Operating Margin | — | — | -3885.3% | -2164.4% | — | — |
| Net Profit Margin | — | — | -4391.4% | -2283.4% | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | -21.0% | -21.0% | -17.7% | -15.1% | -5.4% | -168.4% |
| ROA | -16.4% | -16.4% | -15.3% | -14.1% | -5.2% | -60.7% |
| ROIC | -11.1% | -11.1% | -10.8% | -10.4% | -4.1% | — |
| ROCE | -15.5% | -15.5% | -14.3% | -13.8% | -5.3% | — |
GELS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $4M ($4M total debt minus $24522 cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.25 | 0.25 | 0.13 | 0.07 | 0.01 | 0.77 |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.25 | 0.11 | 0.06 | -0.00 | -0.67 |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -5.03 | -5.03 | -7.69 | -18.30 | -499.32 | — |
GELS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.08x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 0.67x to 0.08x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.08 | 0.08 | 0.73 | 0.67 | 1.59 | 2.50 |
| Quick Ratio | 0.08 | 0.08 | 0.66 | 0.58 | 1.59 | 2.50 |
| Cash Ratio | 0.01 | 0.01 | 0.29 | 0.15 | 0.77 | 1.39 |
| Asset Turnover | — | — | 0.00 | 0.01 | — | — |
| Inventory Turnover | 0.51 | — | 0.51 | 1.00 | — | — |
| Days Sales Outstanding | — | — | 1578.49 | 620.14 | — | — |
GELS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Gelteq Limited Ordinary Shares does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $0 | $9M | $9M | $9M | $2M |
Peer Comparison
Compare GELS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 GELSYou | $5M | — | — | — | — | — | -21.0% | -11.1% | — |
 ATXI | $2M | -0.6 | — | — | — | — | -928.4% | — | — |
 DARE | $25M | -6.1 | — | 5.3 | -146110.2% | -239692.2% | — | — | — |
 NUVB | $2B | -8.0 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 AQST | $516M | -5.6 | — | — | 58.3% | -159.5% | — | — | — |
 ORMP | $160M | -8.3 | — | — | — | — | -12.4% | -6.5% | — |
 PCRX | $930M | 147.8 | 9.9 | 6.8 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 PAHC | $2B | 36.3 | 15.7 | 41.8 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 AMRX | $4B | 62.4 | — | 16.0 | 36.9% | -0.2% | 15.7% | -0.2% | — |
 HIMS | $7B | 50.3 | 42.7 | 89.6 | 59.3% | 5.2% | 25.2% | 10.7% | 6.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
See GELS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GELS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GELS vs ATXI
Side-by-side business, growth, and profitability comparison vs Avenue Therapeutics, Inc..
Start ComparisonGELS — Frequently Asked Questions
Quick answers to the most common questions about buying GELS stock.
What is Gelteq Limited Ordinary Shares's ROE?
Gelteq Limited Ordinary Shares's return on equity (ROE) is -21.0%. The historical average is -45.5%.
Is GELS stock overvalued?
Based on historical data, Gelteq Limited Ordinary Shares is trading at valuation metrics that vary. Compare with industry peers and growth rates for a complete picture.